JP6456394B2 - 胎児仮死の診断 - Google Patents
胎児仮死の診断 Download PDFInfo
- Publication number
- JP6456394B2 JP6456394B2 JP2016543421A JP2016543421A JP6456394B2 JP 6456394 B2 JP6456394 B2 JP 6456394B2 JP 2016543421 A JP2016543421 A JP 2016543421A JP 2016543421 A JP2016543421 A JP 2016543421A JP 6456394 B2 JP6456394 B2 JP 6456394B2
- Authority
- JP
- Japan
- Prior art keywords
- fetal
- uric acid
- sample
- pregnant mother
- eclampsia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000033300 perinatal asphyxia Diseases 0.000 title claims description 30
- 238000003745 diagnosis Methods 0.000 title claims description 18
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 79
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 43
- 229940116269 uric acid Drugs 0.000 claims description 43
- 230000035935 pregnancy Effects 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 31
- 201000011461 pre-eclampsia Diseases 0.000 claims description 22
- 210000003296 saliva Anatomy 0.000 claims description 20
- 238000012544 monitoring process Methods 0.000 claims description 16
- 230000008774 maternal effect Effects 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 208000032943 Fetal Distress Diseases 0.000 claims description 6
- 206010016855 Foetal distress syndrome Diseases 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 206010070538 Gestational hypertension Diseases 0.000 claims description 5
- 208000002296 eclampsia Diseases 0.000 claims description 5
- 208000004104 gestational diabetes Diseases 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 4
- 206010070531 Foetal growth restriction Diseases 0.000 claims description 4
- 201000005624 HELLP Syndrome Diseases 0.000 claims description 4
- 230000036772 blood pressure Effects 0.000 claims description 4
- 208000030941 fetal growth restriction Diseases 0.000 claims description 4
- 210000002826 placenta Anatomy 0.000 claims description 4
- 230000002028 premature Effects 0.000 claims description 4
- 230000035606 childbirth Effects 0.000 claims description 3
- 230000035487 diastolic blood pressure Effects 0.000 claims description 2
- 230000009593 intrauterine fetal growth Effects 0.000 claims description 2
- 230000035488 systolic blood pressure Effects 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 9
- 230000002159 abnormal effect Effects 0.000 description 7
- 238000007726 management method Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000003754 fetus Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010003497 Asphyxia Diseases 0.000 description 3
- 230000006609 metabolic stress Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004578 fetal growth Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- 206010061452 Complication of pregnancy Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000036818 High risk pregnancy Diseases 0.000 description 1
- 206010021718 Induced labour Diseases 0.000 description 1
- 206010051133 Meconium in amniotic fluid Diseases 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 208000019547 Placental disease Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000016599 Uterine disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000025934 placenta disease Diseases 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000010340 saliva test Methods 0.000 description 1
- 201000005608 severe pre-eclampsia Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
唾液の試料を、出産前に産婦人科通院中の一連の妊娠中の被験者から脱脂綿棒を舌下に置くことにより採集した。全血試料中尿酸測定向けの標準手動式尿酸計測器用の試験片上に、各綿棒から一滴の唾液を搾り出した。次いで、試料を製造者の指示書に従って試験し、そして測定尿酸値を計測器上に表示し、記録した。
尿酸濃度を、149人の女性の無作為な試料から、妊娠第6週より実施例1に従って決定した。これらのデータは、平均唾液尿酸が6週間の約100μmol/lから40週間の約250μmol/lまで妊娠期間とは非線形に増大し、増大率は第30週から第40週に上昇したことを示す。
表1.子癇前症を有すると診断された被験者
表2.小新生児(small baby)(約2500gまたはそれ以下)で新生児集中治療室に入室
表3.糖尿病を含む他の病状を伴う被験者
表4.異常唾液尿酸結果を伴う正常妊娠
特定診断方法を開発するために、実施例2からのデータセットを再解析した。それが最初の妊娠であり、妊娠上の問題が起こる臨床上リスクが低く(被験者の医療記録にそうではない旨の情報がないものと定義)、被験者の年齢が18歳〜40歳であった場合、その被験者を再解析のために含めた。
実施例1に従って唾液尿酸塩濃度を決定し、標準法を用いて血液尿酸塩濃度を決定した。唾液中および血中の尿酸塩値を50時間の期間にわたって2時間ごとに1人の被験者において測定した。唾液尿酸塩および血液尿酸塩の両方とも、このモニタリング期間にわたって変動した(図1)。しかし、唾液尿酸値の増加または減少は、血液尿酸塩値の対応する増加または減少と常に関連したわけではなかった(図1)。唾液尿酸塩に対する血液尿酸塩のプロットは、これらの2つの尿酸塩測定値の間に有用な相関がなく、データが広範に点在することを示す(図2;線形r2=0.1028)。したがって、血液尿酸塩は、唾液尿酸塩を予測しなかった。
Claims (16)
- 胎児仮死の診断および/またはモニタリングに用いるための測定データの取得方法であって、妊娠母体から取得した1つまたはそれ以上の試料中の唾液中尿酸値を測定する工程を含み、該胎児仮死が、子癇前症により生じたもの以外である、方法。
- 前記妊娠母体が、胎児仮死を生じ得る状態を有すると知られていない、請求項1に記載の方法。
- 前記妊娠母体が約18歳〜40歳の間である、請求項1または請求項2に記載の方法。
- 前記妊娠母体が臨床上正常な血圧を有する、請求項1から3のいずれかに記載の方法。
- 前記妊娠母体が臨床上正常な尿中蛋白値を有する、請求項1から4のいずれかに記載の方法。
- 前記妊娠母体が、140mmHgまたはそれ以下の収縮期血圧および90mmHgまたはそれ以下の拡張期血圧を有する、請求項4または請求項5に記載の方法。
- 前記妊娠母体が、24時間尿試料中300mg未満、好ましくは150mg未満の蛋白を有する、請求項5または請求項6に記載の方法。
- 前記試料中の臨床上高い尿酸値が、胎児仮死を示す、請求項1から7のいずれかに記載の方法。
- 前記妊娠母体から取得した1つまたはそれ以上の試料中の唾液中尿酸値が、約275μmol/lを上回り、好ましくは約350μmol/lを上回り、より好ましくは約400μmol/lを上回る、請求項8に記載の方法。
- 異なる日に取得された2つまたはそれ以上の試料、好ましくは3つまたはそれ以上の試料、必要に応じて4つまたはそれ以上の試料中で高い尿酸値が、胎児仮死を示す、請求項8または請求項9に記載の方法。
- 前記試料が週に1回取得される、請求項1から10のいずれかに記載の方法。
- 前記試料が妊娠第20週より出産まで取得される、請求項1から11のいずれかに記載の方法。
- 前記試料が舌下腺唾液である、請求項1から12のいずれかに記載の方法。
- 前記胎児仮死が、HELLP症候群、子癇、妊娠性糖尿病、妊娠性高血圧、前期破水、癒着胎盤および子宮内胎児発育遅延の1つまたはそれ以上を示す、請求項1から13のいずれかに記載の方法。
- 胎児仮死の指標としての、母体唾液中尿酸値の使用であって、該胎児仮死が子癇前症により生じたものでない、使用。
- HELLP症候群、子癇、妊娠性糖尿病、妊娠性高血圧、前期破水、癒着胎盤および子宮内胎児発育遅延の1つまたはそれ以上の指標としての、請求項15に記載の母体唾液中尿酸値の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1316668.1 | 2013-09-19 | ||
GBGB1316668.1A GB201316668D0 (en) | 2013-09-19 | 2013-09-19 | Diagnosis of foetal distress |
PCT/EP2014/070053 WO2015040190A1 (en) | 2013-09-19 | 2014-09-19 | Diagnosis of foetal distress |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016531305A JP2016531305A (ja) | 2016-10-06 |
JP2016531305A5 JP2016531305A5 (ja) | 2017-09-07 |
JP6456394B2 true JP6456394B2 (ja) | 2019-01-23 |
Family
ID=49553104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016543421A Active JP6456394B2 (ja) | 2013-09-19 | 2014-09-19 | 胎児仮死の診断 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20160231306A1 (ja) |
EP (1) | EP3047269B1 (ja) |
JP (1) | JP6456394B2 (ja) |
CA (1) | CA2922894C (ja) |
DK (1) | DK3047269T3 (ja) |
ES (1) | ES2687971T3 (ja) |
GB (1) | GB201316668D0 (ja) |
WO (1) | WO2015040190A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7018023B2 (ja) * | 2016-04-14 | 2022-02-09 | モーガン イノベーション アンド テクノロジー リミテッド | 体液中の被分析物のレベルを測定するための方法およびデバイス |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0313828D0 (en) * | 2003-06-16 | 2003-07-23 | Owen Smith Brian D O | Salivary urate for diagnosis of pre-eclampsia |
-
2013
- 2013-09-19 GB GBGB1316668.1A patent/GB201316668D0/en not_active Ceased
-
2014
- 2014-09-19 DK DK14772109.6T patent/DK3047269T3/en active
- 2014-09-19 JP JP2016543421A patent/JP6456394B2/ja active Active
- 2014-09-19 EP EP14772109.6A patent/EP3047269B1/en active Active
- 2014-09-19 CA CA2922894A patent/CA2922894C/en active Active
- 2014-09-19 ES ES14772109.6T patent/ES2687971T3/es active Active
- 2014-09-19 WO PCT/EP2014/070053 patent/WO2015040190A1/en active Application Filing
- 2014-09-19 US US15/023,002 patent/US20160231306A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2016531305A (ja) | 2016-10-06 |
WO2015040190A1 (en) | 2015-03-26 |
GB201316668D0 (en) | 2013-11-06 |
ES2687971T3 (es) | 2018-10-30 |
CA2922894A1 (en) | 2015-03-26 |
DK3047269T3 (en) | 2018-09-17 |
CA2922894C (en) | 2022-05-03 |
EP3047269B1 (en) | 2018-08-01 |
US20160231306A1 (en) | 2016-08-11 |
EP3047269A1 (en) | 2016-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Haws et al. | Reducing stillbirths: screening and monitoring during pregnancy and labour | |
Barber et al. | Contributing indications to the rising cesarean delivery rate | |
Westgren et al. | Lactate compared with pH analysis at fetal scalp blood sampling: a prospective randomised study | |
US12023178B2 (en) | Method of detecting sepsis using vital signs, including systolic blood pressure, hematology parameters, and combinations thereof | |
US20170052193A1 (en) | Fertility and pregnancy monitoring device and method | |
CN104380104A (zh) | 先兆子痫筛查法 | |
Buhling et al. | The usefulness of glycosuria and the influence of maternal blood pressure in screening for gestational diabetes | |
Sert | Prognostic capacity of inferior vena cava diameter for severe postpartum hemorrhage | |
Lin et al. | The value of serum uric acid in predicting adverse pregnancy outcomes of women with hypertensive disorders of pregnancy | |
JP6456394B2 (ja) | 胎児仮死の診断 | |
Lauszus et al. | Ambulatory blood pressure as predictor of preeclampsia in diabetic pregnancies with respect to urinary albumin excretion rate and glycemic regulation | |
Pattinson et al. | Umbilical artery resistance index as a screening test for fetal well-being. I: Prospective revealed evaluation | |
Gribbin et al. | Assessing fetal health | |
Nesrallah et al. | The effect of timing of removal of wound dressing on surgical site infection rate after cesarean delivery [23N] | |
Lindberg | Epidemiology of hypertension during pregnancy | |
Mehreen et al. | A case-control study of postpartum sepsis risk factors in women | |
KR102482468B1 (ko) | 조산에 대한 정보 제공 방법 및 이를 적용한 디바이스 | |
Yusuf et al. | Relationship between abnormal cardiography and cord blood pH at birth in term pregnancies | |
RU2444280C2 (ru) | Способ дифференциальной диагностики гипертензивных расстройств при беременности | |
RU2521359C2 (ru) | Способ определения степени тяжести гестоза у беременных | |
Yosef et al. | Determinants of premature membrane rupture among mothers receiving labor care at different public hospitals in Northeast Ethiopia: An unmatched case control study | |
Oliver et al. | Fetal Death | |
Higgins et al. | The Berlin Questionnaire for Assessment of Sleep-disordered Breathing Risk in Parturients and Nonpregnant Women | |
Premila et al. | Intrapartum fetal surveillance | |
Poon et al. | Inter-arm blood pressure differences in pregnant women |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160318 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170725 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170725 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20180423 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180622 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181023 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181127 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181218 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6456394 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |